Bisabolol, a naturally occurring monocyclic sesquiterpene alcohol derived primarily from Matricaria chamomilla (German chamomile), has been increasingly incorporated into dermatological formulations for its anti-inflammatory and skin-soothing properties. Several studies have investigated its efficacy in the management of dermatitis, particularly atopic and contact dermatitis. Bisabolol exhibits notable anti-inflammatory effects by inhibiting the synthesis of pro-inflammatory cytokines (such as TNF-α and IL-1β) and reducing the activation of nuclear factor kappa B (NF-κB) in skin cells. This helps to decrease skin redness, swelling, and irritation—common features of dermatitis.

In addition to its anti-inflammatory action, bisabolol has demonstrated antimicrobial and antioxidant activities, which can further benefit compromised skin barriers typical in dermatitis patients. Its skin-penetrating properties also enhance the delivery of other active ingredients in topical formulations, making it a popular excipient in combination therapies.

While much of the evidence comes from laboratory (in vitro and animal) studies and small clinical trials, there is a growing body of data supporting bisabolol’s safety and efficacy in reducing symptoms associated with dermatitis. However, large-scale, high-quality human clinical trials are still needed for definitive conclusions, which is why the evidence level is rated as moderate (3/5). Overall, its use is scientifically justified and supported by current research, though more robust clinical data would be beneficial.